Akito Maeshima

3.1k citations
91 papers · 2.4k indexed · h-index 29
Topics
Renal and related cancers (31 papers)Renal Diseases and Glomerulopathies (14 papers)TGF-β signaling in diseases (13 papers)
Journals
JAMASHILAP Revista de lepidopterologíaPLoS ONE

In The Last Decade

Akito Maeshima

87 papers receiving 2.4k citations

Peers

Akito Maeshima
Comparison fields: 5 of 94
  • Molecular Biology 1.4k
  • Surgery 554
  • Nephrology 542
  • Pulmonary and Respiratory Medicine 403
  • Rheumatology 381
Replace Sophie Ferlicot with:
Sophie Ferlicot France
Maria Lucia Angelotti Italy
Nancy A. Noble United States
Gero von Gersdorff Germany
Stefan Gauer Germany
Elena Gagliardini Italy
Costanza Sagrinati Italy
Yasunori Utsunomiya Japan
Ana Merino Spain
Thomas P. Haverty United States
Akito Maeshima relative to Sophie Ferlicot France Sophie Ferlicot's profile →
Citations per field
00.5×1.5×2.2×
Sophie Ferlicot · 1×
Citations per year

Countries citing papers authored by Akito Maeshima

Since Specialization
Citations

This map shows the geographic impact of Akito Maeshima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Akito Maeshima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Akito Maeshima more than expected).

Fields of papers citing papers by Akito Maeshima

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Akito Maeshima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Akito Maeshima. The network helps show where Akito Maeshima may publish in the future.

Co-authorship network of co-authors of Akito Maeshima

This figure shows the co-authorship network connecting the top 25 collaborators of Akito Maeshima. A scholar is included among the top collaborators of Akito Maeshima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Akito Maeshima. Akito Maeshima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
#WorkIndexed citations
1 0
2 0
3 0
4 3
5 3
6 6
7 2
8 7
9 1
10 1
11 13
12 30
13 24
14 67
15 22
16 21
17 39
18 61
19 21
20 43

About Akito Maeshima

Akito Maeshima is a scholar working on Nephrology, Rheumatology and Urology, having authored 91 papers that have together received 2.4k indexed citations. Recurring topics across this work include Renal and related cancers (31 papers), Renal Diseases and Glomerulopathies (14 papers) and TGF-β signaling in diseases (13 papers). The work is most often cited by research in Nephrology (542 citations), Rheumatology (381 citations) and Molecular Biology (1.4k citations). Akito Maeshima has collaborated with scholars based in Japan, United States and United Kingdom. Frequent co-authors include Yoshihisa Nojima, Shin Yamashita, Itaru Kojima, Keiju Hiromura, Hidekazu Ikeuchi, Yoriaki Kaneko, Takashi Kuroiwa, Toru Sakairi, Sanjay K. Nigám and You-Qing Zhang. Their work appears in journals such as JAMA, SHILAP Revista de lepidopterología and PLoS ONE.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026